Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RNA

Avidity Biosciences Inc

Jul 26 • 04:00PM ET

48.14

Dollar change +3.42
Percentage change 7.65	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF XBI IWO IBB SCHA VTWO VHT DWAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.95	Insider Own	9.54%	Shs Outstand	95.64M	Perf Week	6.69%
Market Cap	4.60B	Forward P/E	-	EPS next Y	-3.36	Insider Trans	-10.44%	Shs Float	86.51M	Perf Month	20.62%
Income	-228.68M	PEG	-	EPS next Q	-0.84	Inst Own	91.74%	Short Float	14.92%	Perf Quarter	102.01%
Sales	10.87M	P/S	423.56	EPS this Y	-6.95%	Inst Trans	-0.67%	Short Ratio	8.31	Perf Half Y	359.79%
Book/sh	8.69	P/B	5.54	EPS next Y	-8.03%	ROA	-29.22%	Short Interest	12.91M	Perf Year	417.08%
Cash/sh	9.58	P/C	5.03	EPS next 5Y	-	ROE	-32.91%	52W Range	4.82 - 47.05	Perf YTD	431.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-57.60%	ROI	-27.34%	52W High	2.32%	Beta	0.88
Dividend TTM	-	Quick Ratio	12.47	Sales past 5Y	148.90%	Gross Margin	64.89%	52W Low	897.72%	ATR (14)	2.14
Dividend Ex-Date	-	Current Ratio	12.47	EPS Y/Y TTM	12.25%	Oper. Margin	-2347.64%	RSI (14)	70.59	Volatility	4.65% 4.78%
Employees	253	Debt/Eq	0.01	Sales Y/Y TTM	12.50%	Profit Margin	-2103.78%	Recom	1.00	Target Price	61.56
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-6.13%	Payout	-	Rel Volume	0.65	Prev Close	44.72
Sales Surprise	36.18%	EPS Surprise	0.77%	Sales Q/Q	58.67%	Earnings	May 09 AMC	Avg Volume	1.55M	Price	48.14
SMA20	12.31%	SMA50	33.26%	SMA200	144.97%	Trades		Volume	1,004,355	Change	7.65%

Date	Action	Analyst	Rating Change	Price Target Change
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$29
Jul-12-22	Initiated	Raymond James	Strong Buy	$29
Sep-07-21	Initiated	Evercore ISI	Outperform	$50
Jun-17-21	Initiated	Needham	Buy	$50
Apr-26-21	Resumed	Credit Suisse	Outperform	$37
Jul-07-20	Initiated	Wells Fargo	Overweight	$60
Jul-07-20	Initiated	Wells Fargo	Overweight
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform	$34
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform

Show Previous Ratings

Jul-23-24 07:00AM	3 Russell 2000 Growth Stocks That Could Be Worth the Risk (Motley Fool)
Jul-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-03-24 06:53AM	Aviditys FSHD drug del-brax shows promise in Phase I/II trial (Clinical Trials Arena)
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Loading…
Jun-20-24 09:00AM	Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day (PR Newswire)
Jun-17-24 04:05PM	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jun-14-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Jun-13-24 08:00PM	Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock (PR Newswire)
10:39AM	Avidity (RNA) Up 33% on Rare Muscle Disease Study Results (Zacks)
Jun-12-24 04:04PM	The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record (Investor's Business Daily) +32.64%
04:01PM	Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
07:45AM	Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss (BioPharma Dive)
07:00AM	Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire)
May-29-24 04:05PM	Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress (PR Newswire)
08:45AM	Loading…
08:45AM	2 Potentially High-Reward Growth Stocks to Buy Right Now (Motley Fool)
May-23-24 06:00AM	Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound (InvestorPlace) -7.26%
May-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-19-24 09:03AM	Bank of America Predicts up to ~200% Surge for These 2 Strong Buy Stocks (TipRanks)
May-17-24 03:24AM	Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing (MT Newswires)
May-15-24 09:00AM	Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors (PR Newswire)
May-09-24 11:55PM	RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
May-08-24 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
12:27PM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1 (MT Newswires)
06:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire)
Apr-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.29%
Apr-04-24 01:30AM	Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares (GuruFocus.com) -11.07%
Mar-27-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
07:01PM	Loading…
Mar-15-24 07:01PM	Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA) (GuruFocus.com)
Mar-04-24 04:02PM	Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy (Investor's Business Daily) -6.22%
07:00AM	Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR Trial (PR Newswire)
Feb-29-24 12:00PM	Avidity Biosciences Honors Rare Disease Day (PR Newswire) +19.92%
07:00AM	Avidity Biosciences Announces Oversubscribed $400 Million Private Placement (PR Newswire)
Feb-28-24 05:20PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:40PM	Avidity Biosciences Inc (RNA) Reports Year-End Financials and Clinical Progress (GuruFocus.com)
04:05PM	Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights (PR Newswire)
Feb-27-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire) +5.51%
Feb-26-24 06:55AM	3 Highly Rated Biotech Stocks to Buy for 300% Gains (InvestorPlace)
Feb-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-20-24 09:00AM	Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Feb-15-24 05:00PM	Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Jan-29-24 08:54AM	Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Jan-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-05-24 08:30AM	Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth (PR Newswire)
Dec-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.10%
Dec-13-23 08:30AM	Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44 Trial for Duchenne Muscular Dystrophy (PR Newswire) +10.28%
Nov-29-23 09:03AM	Avidity (RNA) Expands Collaboration With BMY, Shares Rise (Zacks) +10.31%
Nov-28-23 10:09AM	Why Is Avidity Biosciences (RNA) Stock Up 15% Today? (InvestorPlace) +14.94%
10:02AM	Avidity Stock Soars on Collaboration Deal With Bristol Myers (Barrons.com)
07:01AM	Bristol Myers pours $100M into RNA drugs for cardiovascular diseases (BioPharma Dive)
06:30AM	Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology (PR Newswire)
Nov-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.63%
09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Nov-08-23 06:12PM	Avidity Biosciences Inc (RNA) Reports Third Quarter 2023 Financial Results and Recent Highlights (GuruFocus.com) -7.03%
04:05PM	Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights (PR Newswire)
Oct-23-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.49%
Oct-07-23 07:30AM	Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 (PR Newswire)
Sep-26-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society (PR Newswire)
Sep-25-23 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Sep-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.33%
Sep-11-23 07:28PM	Down More Than 50%: Analysts Say Buy These 2 Beaten-Down Stocks Before They Rebound (TipRanks) +9.74%
Sep-07-23 09:00AM	Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs (PR Newswire)
Aug-31-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference (PR Newswire) -5.14%
Aug-30-23 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-15-23 09:00AM	Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Aug-08-23 07:15PM	Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights (PR Newswire)
Jul-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-12-23 07:24AM	Avidity Biosciences (NASDAQ:RNA) shareholders have endured a 59% loss from investing in the stock three years ago (Simply Wall St.)
Jun-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-20-23 09:00AM	Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day (PR Newswire)
Jun-08-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress (PR Newswire)
May-22-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +11.65%
May-17-23 12:38PM	FDA Eases Partial Hold On Avidity Biosciences' Investigational Drug Study In Type Of Dystrophy (Benzinga)
07:00AM	Avidity Biosciences Announces FDA Eases Partial Clinical Hold on AOC 1001 Providing a Clear Path Forward to Finalize Pivotal Dose and Phase 3 Design in Adults with Myotonic Dystrophy Type 1 (PR Newswire)
May-09-23 06:15PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights (PR Newswire)
May-04-23 09:00PM	Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar? (Zacks)
Apr-28-23 10:08AM	Avidity Biosciences Touts Encouraging Data From Myotonic Dystrophy Type 1 Study (Benzinga) -14.78%
Apr-27-23 03:40PM	Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1 (PR Newswire) -16.09%
Apr-24-23 09:00AM	Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping (PR Newswire)
Apr-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-17-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting (PR Newswire) +8.08%
Apr-13-23 09:00AM	Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA Trial on April 27, 2023 (PR Newswire) +9.08%
Apr-11-23 11:23AM	After Falling 18% in 1 Day, Is This Growth Stock Done For? (Motley Fool)
Apr-05-23 10:14AM	Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates (Zacks)
Mar-31-23 11:44AM	Avidity (RNA) Down on Update From Neuromuscular Disease Study (Zacks) -8.63%
Mar-30-23 04:16PM	Avidity Bio Crashes 17% After 'Rarer Than Rare' Event Sidelines Key Study (Investor's Business Daily) -16.83%
03:25PM	Why Avidity Biosciences Shares Are Sliding Today (Benzinga)
07:00AM	Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA Trial at AAN Annual Meeting (PR Newswire)
Mar-25-23 10:17AM	Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Mar-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.28%
Mar-13-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference (PR Newswire)
Mar-01-23 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Feb-28-23 07:45PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights (PR Newswire)
09:00AM	Avidity Biosciences Honors Rare Disease Day® (PR Newswire)

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEVIN ARTHUR A	Director	Jul 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Jul 23 04:22 PM
LEVIN ARTHUR A	Director	Jul 19 '24	Sale	45.01	5,000	225,069	14,830	Jul 23 04:22 PM
Boyce Sarah	President and CEO	Jul 09 '24	Option Exercise	1.24	28,000	34,720	233,043	Jul 11 04:07 PM
Boyce Sarah	President and CEO	Jul 09 '24	Sale	39.93	28,000	1,118,082	205,043	Jul 11 04:07 PM
LEVIN ARTHUR A	Director	Jun 20 '24	Option Exercise	1.24	5,000	6,200	19,830	Jun 21 04:19 PM
LEVIN ARTHUR A	Director	Jun 20 '24	Sale	37.59	5,000	187,950	14,830	Jun 21 04:19 PM
Boyce Sarah	President and CEO	Jun 18 '24	Sale	39.13	32,074	1,255,040	142,543	Jun 20 06:47 PM
MacLean Michael F	Chief Financial Officer	Jun 18 '24	Sale	39.13	11,228	439,345	57,865	Jun 20 06:48 PM
Flanagan W. Michael	CSTO	Jun 18 '24	Sale	39.13	10,106	395,445	50,765	Jun 20 06:47 PM
McCarthy Teresa	Chief Human Resources Officer	Jun 18 '24	Sale	39.13	9,864	385,972	32,171	Jun 20 06:49 PM
Boyce Sarah	President and CEO	Jun 14 '24	Option Exercise	1.24	35,767	44,351	147,884	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 14 '24	Sale	40.08	35,767	1,433,484	112,117	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 13 '24	Option Exercise	1.24	164,233	203,649	276,350	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 13 '24	Sale	40.08	164,233	6,581,802	112,117	Jun 14 06:58 PM
LEVIN ARTHUR A	Director	Jun 13 '24	Sale	40.08	60,000	2,404,782	153,872	Jun 14 07:03 PM
MacLean Michael F	Chief Financial Officer	Jun 12 '24	Option Exercise	8.82	104,245	919,441	148,338	Jun 14 07:07 PM
Boyce Sarah	President and CEO	Jun 12 '24	Option Exercise	1.24	100,000	124,000	212,117	Jun 14 06:58 PM
MacLean Michael F	Chief Financial Officer	Jun 12 '24	Sale	35.72	104,245	3,723,141	44,093	Jun 14 07:07 PM
Boyce Sarah	President and CEO	Jun 12 '24	Sale	35.73	100,000	3,573,020	112,117	Jun 14 06:58 PM
LEVIN ARTHUR A	Director	Jun 12 '24	Sale	35.07	40,000	1,402,628	213,872	Jun 14 07:03 PM
Boyce Sarah	President and CEO	Jun 04 '24	Option Exercise	1.24	28,000	34,720	140,117	Jun 05 05:46 PM
Boyce Sarah	President and CEO	Jun 04 '24	Sale	27.42	28,000	767,780	112,117	Jun 05 05:46 PM
LEVIN ARTHUR A	Director	May 20 '24	Option Exercise	1.24	5,000	6,200	19,830	May 21 05:05 PM
LEVIN ARTHUR A	Director	May 20 '24	Sale	29.90	5,000	149,481	14,830	May 21 05:05 PM
MacLean Michael F	Chief Financial Officer	May 14 '24	Option Exercise	8.82	75,000	661,500	119,093	May 16 06:25 PM
MacLean Michael F	Chief Financial Officer	May 14 '24	Sale	28.28	75,000	2,121,045	44,093	May 16 06:25 PM
Boyce Sarah	President and CEO	May 07 '24	Option Exercise	1.24	28,000	34,720	140,117	May 07 09:52 PM
Boyce Sarah	President and CEO	May 07 '24	Sale	25.54	28,000	715,050	112,117	May 07 09:52 PM
LEVIN ARTHUR A	Director	Apr 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Apr 22 05:28 PM
LEVIN ARTHUR A	Director	Apr 19 '24	Sale	22.82	5,000	114,123	14,830	Apr 22 05:28 PM
LEVIN ARTHUR A	Director	Apr 03 '24	Sale	27.11	20,000	542,214	253,872	Apr 03 08:26 PM
Boyce Sarah	President and CEO	Apr 02 '24	Option Exercise	1.24	28,000	34,720	140,117	Apr 03 06:16 PM
Boyce Sarah	President and CEO	Apr 02 '24	Sale	26.25	28,000	734,919	112,117	Apr 03 06:16 PM
LEVIN ARTHUR A	Director	Mar 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Mar 21 04:10 PM
LEVIN ARTHUR A	Director	Mar 19 '24	Sale	23.97	5,000	119,848	14,830	Mar 21 04:10 PM
MacLean Michael F	Chief Financial Officer	Mar 13 '24	Option Exercise	8.82	40,000	352,800	84,093	Mar 15 04:12 PM
MacLean Michael F	Chief Financial Officer	Mar 13 '24	Sale	24.52	40,000	980,760	44,093	Mar 15 04:12 PM
Boyce Sarah	President and CEO	Mar 12 '24	Option Exercise	1.24	28,000	34,720	140,117	Mar 12 05:29 PM
LEVIN ARTHUR A	Director	Mar 12 '24	Option Exercise	1.24	25,000	31,000	42,471	Mar 12 08:41 PM
Boyce Sarah	President and CEO	Mar 12 '24	Sale	22.63	28,000	633,682	112,117	Mar 12 05:29 PM
LEVIN ARTHUR A	Director	Mar 12 '24	Sale	22.03	27,641	609,017	14,830	Mar 12 08:41 PM
Boyce Sarah	President and CEO	Mar 08 '24	Option Exercise	1.24	84,000	104,160	196,117	Mar 12 05:29 PM
Boyce Sarah	President and CEO	Mar 08 '24	Sale	21.39	84,000	1,796,710	112,117	Mar 12 05:29 PM
Boyce Sarah	President and CEO	Mar 01 '24	Option Exercise	1.24	84,000	104,160	196,117	Mar 05 04:53 PM
Boyce Sarah	President and CEO	Mar 01 '24	Sale	20.13	84,000	1,691,306	112,117	Mar 05 04:53 PM
Boyce Sarah	President and CEO	Jan 22 '24	Sale	10.13	5,092	51,582	44,008	Jan 23 03:13 PM
Flanagan W. Michael	CSTO	Jan 22 '24	Sale	10.13	4,129	41,827	35,871	Jan 23 03:12 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 22 '24	Sale	10.13	2,065	20,918	17,035	Jan 23 03:11 PM
LEVIN ARTHUR A	Director	Jan 22 '24	Sale	10.13	1,859	18,832	17,471	Jan 23 03:14 PM
MacLean Michael F	Chief Financial Officer	Jan 22 '24	Sale	10.13	1,616	16,370	16,884	Jan 23 03:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNA

Avidity Biosciences Inc

Upgrade your FINVIZ experience